The World Health Organization (WHO) has made new recommendations for the usage of two monoclonal antibodies to treat the Ebola virus in its first published guideline.

mAb114 (Ansuvimab; Ebanga) and REGN-EB3 (Inmazeb) are the two monoclonal antibody treatments recommended by the WHO.

The health agency urged the global community to boost access to these lifesaving therapies.

This development follows a systematic assessment and meta-analysis of randomised clinical trials of therapies for the disease.

These trials were carried out during Ebola outbreaks, with the largest of them being conducted in the Democratic Republic of the Congo.

The guidelines will back health care providers caring for Ebola patients, as well as policymakers linked to readiness and response to the disease outbreak. 

The guidance also complements clinical care recommendations that outline the optimal supportive care patients with Ebola should get for better recovery.

The two recommended antibody therapies can be used for all Ebola patients, including pregnant and breastfeeding women, children, elderly individuals, and newborns of mothers with Ebola within the initial seven days following birth. 

Guideline Development Group of WHO-selected experts co-chair Dr Richard Kojan said: “This therapeutic guide is a critical tool to fight Ebola. 

“It will help reassure the communities, healthcare workers and patients that this life-threatening disease can be treated, thanks to effective drugs. 

“From now on, people infected with the Ebola virus will have a greater chance of recovering if they seek care as early as possible.”

The WHO also advised against the use of some therapeutics for treating Ebola patients, including ZMapp and remdesivir.